Clinical trial designs for predictive biomarker validation: one size does not fit all. (Q34097089)

31 July 2017

title

Clinical trial designs for predictive biomarker validation: one size does not fit all. (English)

1 reference

31 July 2017

0 references

Daniel J Sargent

2

1 reference

ORCID Public Data File 2021

author name string

Sumithra J Mandrekar

series ordinal

1

1 reference

31 July 2017

publication date

1 January 2009

1 reference

Journal of Biopharmaceutical Statistics

31 July 2017

published in

1 reference

31 July 2017

volume

19

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

530-542

1 reference

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Cancer diagnostics: decision criteria for marker utilization in the clinic

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Erlotinib in previously treated non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Clinical trial designs for predictive marker validation in cancer treatment trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Prognostic and predictive markers in cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Clinical trial methods to discover and validate predictive markers for treatment response in cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2931323

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

5 July 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400902802458

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400902802458

Clinical trial designs for prospective validation of biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400902802458

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400902802458

Herceptin: increasing survival in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10543400902802458

Issues in clinical trial design for tumor marker studies

21 January 2018

1 reference

12 December 2020

On the efficiency of targeted clinical trials

1 reference

12 December 2020

HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial

1 reference

12 December 2020

EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

1 reference

12 December 2020

Evaluating the efficiency of targeted designs for randomized clinical trials

1 reference

12 December 2020

10.1080/10543400902802458

Identifiers

DOI

1 reference

31 July 2017

1 reference

31 July 2017

1 reference